Tepnel Life Sciences (UK) reports reduced net loss:
This article was originally published in Clinica
Tepnel Life Sciences (UK) has reduced its loss to £890,000 ($1.4 million) in the half-year to the end of March from £1.01 million a year earlier. Anthony Martin, chairman since February, believes the company has sufficient financial resources to support its plans for the rest of 1995. Tepnel intends to concentrate on the introduction of its DNA technology in the genetic and cancer testing markets. The company says it is developing Solid Phase Amplification (SPA), a new method of DNA detection as an extension to its DARAS technology, for automated identification of DNA.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.